Catalyst

Slingshot members are tracking this event:

EyeGate (EYEG) Announces Top-Line Results for Phase 2b Trial of EGP-437 in Cataract Surgery

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
EYEG

100%

Additional Information

Clinical Data Although, EGP-437 demonstrated a higher rate of success compared to vehicle at all time points, the co-primary endpoints of proportion of subjects with an anterior chamber cell (ACC) count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1 did not show statistical significance.
http://www.eyegateph...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 05, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 2b Data, Egp-437, Cataract Surgery